This announcement is a separate document:
エーザイ：エーザイは、ファルレツズマブエクテリブリン（FZEC）抗体薬物複合体（ADC）の単独開発と商品化への移行を発表しました
Eisai: Eisai has announced the transition to developing and commercializing the Farletsuzumab Ecteinascidin-1 Antibody Drug Complex (ADC) on its own.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.